Draft monograph: Lixisenatide — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. Effect estimates are given without naming the comparator — arising from DRAFT-LIXISENATIDE/009. The comparator is now stated in every outcome row, and estimates against different comparators are reported in separate tables with the comparator named in the table caption.
2. The compound is supplied under names the monograph does not list — arising from DRAFT-LIXISENATIDE/006. The synonym list is extended to include every name the Institute can evidence from a document it holds, each recorded with its source. Names asserted without a supporting document are not added, and the distinction is stated at the head of the list.
3. The analytical section is longer than the clinical assessment it accompanies — arising from DRAFT-LIXISENATIDE/007. The analytical section is reduced to compound-specific content and cross-references the relevant standards for the general procedure, which shortens it substantially without removing what is not available elsewhere.
4. The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-LIXISENATIDE/005. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.
5. What happens when the compound is stopped is not addressed — arising from DRAFT-LIXISENATIDE/008. Discontinuation trajectory is now an assessed outcome in every monograph where a contributing trial measured it, and a recorded evidence gap in every monograph where none did, so that its absence is visible rather than silent.
6. Quantitative claims are reproduced without the method that produced them — arising from DRAFT-LIXISENATIDE/003. Every quantitative claim now carries the determination that produced it at the point of use, and figures obtained by non-comparable methods are no longer presented in the same row or sentence.
7. Point estimates are given without an interval — arising from DRAFT-LIXISENATIDE/004. Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.
8. Storage and reconstitution guidance is given without stating what it rests on — arising from DRAFT-LIXISENATIDE/001. In-use periods now appear only where supported by a cited stability determination on a stated presentation, and elsewhere the monograph records that no in-use stability evidence was identified for this presentation.
9. The population to which the headline estimate applies is not stated with the estimate — arising from DRAFT-LIXISENATIDE/002. Every headline estimate now carries a one-line statement of the population in which it was observed, and the full eligibility criteria are reported in the included-studies table rather than only in the source.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.